- Home
- RDCM vs ARMP Comparison
RDCM vs ARMP Comparison
Compare RDCM & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | ARMP |
|---|---|---|
| Founded | 1985 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 199.7M |
| IPO Year | 1999 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RDCM | ARMP |
|---|---|---|
| Price | $10.13 | $3.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.00 | ★ $17.50 |
| AVG Volume (30 Days) | 48.8K | ★ 106.9K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.56 | N/A |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $2.75 |
| 52 Week High | $16.74 | $14.98 |
Technical Indicators
Market Signals| Indicator | RDCM | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 40.10 |
| Support Level | $10.07 | N/A |
| Resistance Level | $10.79 | $5.63 |
| Average True Range (ATR) | 0.23 | 0.33 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 32.20 | 38.87 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.